low-dose BXOS110

Phase 2Small molecule

BBiocells (Beijing) Biotech Co.,Ltd

low-dose BXOS110 is one of 29 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Activase

Roche

Preclinical

19 2

Zometa

Pfizer

Preclinical

1 3

Folvite

Eli Lilly

Preclinical

1 4

Botox

RRevance Therapeutics, Inc.

Preclinical

2 5

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Alka-Seltzer

AAbbott

Preclinical

1 7

Inderal

Mylan Pharmaceuticals Inc

Botulinum Toxin a

1 9

Anticoagulant

Bayer

Preclinical

1 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stroke1 trial

BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

Recruiting·BBiocells (Beijing) Biotech Co.,Ltd·Phase 2·NCT06322394·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for low-dose BXOS110. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — low-dose BXOS110 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for low-dose BXOS110. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocells (Beijing) Biotech Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBiocells (Beijing) Biotech Co.,Ltd

low-dose BXOS110

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stroke1 trial

References

Drug Info

Quick Facts

Related News